Search results for: Real World Evidence (RWE)
Filter search results
OHE at ISPOR Italy Chapter – Rome: Are Wider Societal Effects Considered in Healthcare Decision-making?
17 May 2016
…wider societal impact is indirect costs, which can arise from reductions in productivity at work or increases in sickness absence, non-employment or early retirement. Based on evidence from a recently…
NICE Recommendation Highlights Role of Social Value Judgements
9 August 2018
…of the disease” (p.20). This has the potential to be controversial. While there is widespread evidence of societal support for prioritising treatment of the severely ill, the evidence on preferences…
New Publication: Advanced Therapy Medicinal Products and Health Technology Assessment
12 October 2018
…the evidence is an aspect of all HTA processes, the specific nature of the evidence that is available for newly approved ATMPs is considered likely to require special consideration. Discounting:…
Dementia
1 September 1992
…for service providers, from all sectors, is to ensure that people with dementia and their carers receive support appropriate to their needs. Current evidence, both from the UK and elsewhere,…
Prescribing, Budgets and Fundholding in General Practice
10 January 1997
…criticised aspects of Conservative health policy. The scheme was introduced without prior appraisal and with minimal consultation. Being untested, no contemporary evidence was available on the potential costs or benefits…
Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?
12 January 2014
…therapy is based on an optimal amount of evidence from relative effectiveness research that is generated and used efficiently across health care systems both within Europe and as between the…
The Impact of New Medicines in the NHS: 70 Years of Innovation
1 August 2018
…Through interviews with experts we identified a shortlist of the most important medicines to have been brought to market, and from a review of the literature and evidence base we…
Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
1 February 2021
…were those known to use some form of valuation of human life: health, social care, transport, and environment. For each country, a literature review was conducted to identify evidence from…
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
…the session and speakers: Dr Amanda Cole, Senior Principal Economist at OHE Josie Godfrey, Director at JG Zebra Consulting Dr Ruth Kim, Value & Evidence Team Leader, Rare Disease and…